FIRMQUARRYResearch workspace

EU_TED process · buyer country DEU · award

Abschluss eines nicht-exklusiven Rabattvertrages gemäß§ 130c Abs. 1 SGB V zwischen der IKK classic und Abacus Medicine und Originalis B.V. zu Bimzelx

['IKK classic']

Procedure 00023be5-73bc-47d8-8e4b-752e983296b6CPV 33600000Healthcare
EUR 1
Data last updated Oct 22, 2026 · Source: Tenders Electronic Daily
Buyer identifier
TED_ORGANISATION: 993-80175-34
Procurement method
Not reported
Tender deadline
Not reported
Contract period
Not reported — Not reported
Native value
EUR 1
USD comparison
Not shown — no auditable FX observation
Official source
Open notice ↗

Description

Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130c Abs. 1 SGB V zwischen der IKK classic und Abacus Medicine und Originalis B.V. zu Bimzelx (Wirkstoff: Bimekizumab, ATC-Code: L04AC21, Vertragslaufzeit: 01.10.2026-30.09.2028)

Suppliers

Official lifecycle

Process timeline

  1. Award announced

    Abschluss eines nicht-exklusiven Rabattvertrages gemäß§ 130c Abs. 1 SGB V zwischen der IKK classic und Abacus Medicine und Originalis B.V. zu Bimzelx

    DEU · eu_tedEUR 1Source ↗

Notice versions

PublicationVersionTypeDateSource
763593-20261can-standardNov 3, 2026Official notice ↗ · XML ↗

Lots

LotCPVPerformanceNUTSValue
LOT-000033600000, 33600000DEUDED21Not reported

Contracts

ContractLotStatusPeriodValue
Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130c Abs. 1 SGB V zwischen der IKK classic und Abacus Medicine und Originalis B.V. zu BimzelxLOT-0000Not reportedNot reported — Not reportedNot reported

Auditable model output

Predictive intelligence

Predictive intelligenceInsufficient historyNo eligible point-in-time model has produced a prediction for this record.

Append-only source history

Source records

RecordDateStagesFetched
3f2ce9a6-42ef-4f31-a8fc-d56f0174b61d:1Nov 3, 2026award_announcedNov 3, 2026